First-in-Human

Quotient has supported more than 100 First-in-Human studies and is a leading provider of services to support the entry of candidates into man. Quotient has been awarded Phase I Supplementary Accreditation by the Medicines and Healthcare products Regulatory Agency (MHRA).  This is one of the highest levels of accreditation in Europe acknowledging our continued commitment to quality and safety, and underpins our status as one of the leading clinical units in Europe.

The combination of more than 20 years experience with advanced science and technology platforms places Quotient in a unique position to support our customers in achieving their early development objectives.

Increasing pressures on R&D productivity place Early Development as a key point to identify those drug candidates with the potential to become “winners” and to eliminate the “losers” prior to significant downstream expenditure. As a result drug candidates are progressed into humans more rapidly in order to collect the key decision making data sets that show the true potential of a candidate drug.

Quotient provides extensive support for FIH studies and is able to accelerate the timeline to transition from discovery to get candidates into man quickly and augment the FIH study to provide an enriched data set.  For more information, see our support for RapidFIH, microdose and ivMicrotracer™ studies.